XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xilio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.33−0.22 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
Xilio Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Market Cap | $48.17M | $164.85M |
| Enterprise Value | -$87.87M | $87.06M |
| PS Ratio | 0.75 | 3.60 |
| PB Ratio | 0.67 | 2.03 |
| P/TBV Ratio | 0.67 | 2.31 |
Enterprise value
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -1.37 | 2.43 |
Income (trailing twelve months)
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Revenue | $64.09M | $57.94M |
| Operating Income | -$31.37M | -$21.44M |
| Net Income | -$21.83M | -$22.46M |
| EBITDA | -$30.03M | -$16.91M |
Margins
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -48.9% | -44.5% |
| Profit Margin | -34.1% | -39.2% |
| EBITDA Margin | -46.9% | -31.3% |
| FCF Margin | -95.6% | -8.85% |
Returns
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -55.0% | -53.1% |
| Return on Assets (ROA) | -15.2% | -41.0% |
| Return on Capital Employed (ROCE) | -26.1% | -37.8% |
Growth
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 327.3% | 6.01% |
Balance sheet
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $136.04M | $62.42M |
| Net Cash (Debt) | $136.04M | $15.68M |
| Net Cash Per Share | $23.53 | $0.66 |
| Equity (Book Value) | $72.26M | $48.79M |
| Book Value Per Share | $12.50 | $1.36 |
| Tangible Book Value | $72.26M | $23.06M |
| Working Capital | $111.27M | $75.77M |
Financial position
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.25 | 3.30 |
| Quick Ratio | 3.98 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$60.60M | -$12.35M |
| Capital Expenditures | -$670.00K | -$1.06M |
| Free Cash Flow | -$61.27M | -$20.28M |
| FCF Per Share | -$10.60 | -$0.42 |
Efficiency
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.44 | 0.38 |
| Revenue Per Employee | $843.32K | $398.96K |
| Profits Per Employee | -$287.22K | -$703.34K |
| Employee Count | 76 | 74 |
Dividends and yields
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -45.3% | -22.7% |
| FCF Yield | -127.2% | -9.07% |
Shares
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 5,782,510 | 58,179,650 |
| Shares Change (YoY) | 166.1% | 11.1% |
| Shares Change (QoQ) | 13.8% | 0.54% |
| Shares Held by Institutions | 47.7% | 59.4% |
Scores
| Measure | Xilio Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -2.98 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Xilio Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.